ID27415A - Komposisi farmaseutik - Google Patents

Komposisi farmaseutik

Info

Publication number
ID27415A
ID27415A IDW20002745A ID20002745A ID27415A ID 27415 A ID27415 A ID 27415A ID W20002745 A IDW20002745 A ID W20002745A ID 20002745 A ID20002745 A ID 20002745A ID 27415 A ID27415 A ID 27415A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
IDW20002745A
Other languages
English (en)
Indonesian (id)
Inventor
Hiroyuki Odaka
Masahiro Yamane
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ID27415A publication Critical patent/ID27415A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20002745A 1998-06-30 1999-06-29 Komposisi farmaseutik ID27415A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18370098 1998-06-30

Publications (1)

Publication Number Publication Date
ID27415A true ID27415A (id) 2001-04-05

Family

ID=16140426

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002745A ID27415A (id) 1998-06-30 1999-06-29 Komposisi farmaseutik

Country Status (16)

Country Link
US (2) US6329403B1 (de)
EP (1) EP1093370B1 (de)
KR (1) KR20010043455A (de)
CN (1) CN1305376A (de)
AR (1) AR019727A1 (de)
AT (1) ATE318138T1 (de)
AU (1) AU754740B2 (de)
BR (1) BR9911656A (de)
CA (1) CA2329004C (de)
DE (1) DE69929996T2 (de)
DK (1) DK1093370T3 (de)
ES (1) ES2255316T3 (de)
ID (1) ID27415A (de)
NO (1) NO20006630L (de)
WO (1) WO2000000195A1 (de)
ZA (1) ZA200006262B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
EP1849475A1 (de) 1999-06-21 2007-10-31 Eli Lilly & Company Synergistische Verwendung von Thiazolidindionen mit glucagonartigem Peptid-1 und Agonisten davon zur Behandlung von nicht insulinabhängigen Diabetes
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
WO2001062295A1 (en) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Drugs containing combined active ingredients
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
WO2002072146A2 (en) * 2001-03-12 2002-09-19 Novartis Ag Combination of nateglinide or repaglinide with at least one further antidiabetic compound
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
WO2003063889A1 (en) * 2002-01-31 2003-08-07 Joslin Diabetes Center, Inc. METHODS OF MODULATING β CELL FUNCTION
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1388352A1 (de) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004078717A1 (en) * 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US20050187266A1 (en) * 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
JP4869072B2 (ja) * 2003-11-14 2012-02-01 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
US20090111742A1 (en) * 2004-01-26 2009-04-30 Alexei Kharitonenkov Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
EP1730310A2 (de) * 2004-03-22 2006-12-13 The Regents Of The University Of California Formulierung zur steigerung der endogenen adiponectin- und leptinproduktion
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7934562B2 (en) * 2004-12-03 2011-05-03 Vetco Gray Scandinavia As Hybrid control system and method
KR100697982B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 로시글리타존의 제조방법
KR100697983B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 신규 중간체 및 이를 이용한 피오글리타존의 제조방법
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2016076A2 (de) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Polymorphe formen von rosiglitazon-hydrobromid und herstellungsverfahren dafür
CA2682608A1 (en) * 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
EP2635296B1 (de) * 2010-11-03 2014-12-24 Arecor Limited Neue zusammensetzung enthaltend glucagon
AU2013343565B2 (en) * 2012-11-06 2018-07-26 Sigrid Therapeutics Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP4072561A4 (de) 2019-12-11 2023-11-29 Inspirna, Inc. Verfahren zur behandlung von krebs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
EP0601001B1 (de) 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ATE293963T1 (de) 1996-02-02 2005-05-15 Merck & Co Inc Verfahren zur behandlung von diabetes und verwandter krankheitszustände.
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
CA2329004C (en) 2009-04-14
ATE318138T1 (de) 2006-03-15
ES2255316T3 (es) 2006-06-16
CN1305376A (zh) 2001-07-25
AR019727A1 (es) 2002-03-13
BR9911656A (pt) 2001-03-20
NO20006630D0 (no) 2000-12-22
CA2329004A1 (en) 2000-01-06
US6329403B1 (en) 2001-12-11
WO2000000195A1 (en) 2000-01-06
ZA200006262B (en) 2001-11-02
DE69929996D1 (de) 2006-04-27
NO20006630L (no) 2001-02-26
DK1093370T3 (da) 2006-05-22
EP1093370A1 (de) 2001-04-25
EP1093370B1 (de) 2006-02-22
DE69929996T2 (de) 2006-11-16
KR20010043455A (ko) 2001-05-25
AU754740B2 (en) 2002-11-21
US20020086885A1 (en) 2002-07-04
AU4291499A (en) 2000-01-17

Similar Documents

Publication Publication Date Title
ID27415A (id) Komposisi farmaseutik
EA199900373A3 (ru) Фармацевтические композиции
NO20005913L (no) Legemiddelsammensetning
NO20015175D0 (no) Farmasöytisk sammensetning
ID29262A (id) Komposisi farmasi
FI991485L (fi) Uusi farmaseuttinen koostumus
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID29089A (id) Sediaan farmasi moksifloksasin
ID27201A (id) Komposisi farmasi
DK1466615T3 (da) Farmaceutisk præparat
DE69928862D1 (de) Zusammensetzung
ID27150A (id) Sediaan levotiroksin bahan farmasi
ID30032A (id) Formulasi farmasi
ID29294A (id) Komposisi farmasi
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ID18698A (id) Komposisi farmasi
ID25857A (id) Komposisi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
EE200100281A (et) Analgeetiline ravimkoostis
EP1124557A4 (de) Pharmazeutische zusammensetzung
ID26215A (id) Komposisi farmasi
ITMI962628A0 (it) Composizione farmaceutica
DE69939964D1 (de) Gelförmige Zusammensetzung
ID23531A (id) Komposisi farmasi
SE9800052D0 (sv) Pharmaceutical compositions